Skip to main content
. Author manuscript; available in PMC: 2014 Feb 25.
Published in final edited form as: Gene Ther. 2009 Dec 17;17(2):158–170. doi: 10.1038/gt.2009.161

Figure 5. The effects of physical and chemical inactivation of replication-competent VSV on the efficacy of VSV virotherapy.

Figure 5

A. Overnight cultures of 2×106 B16ova cells were infected with VSVs (MOI=0.01) for 24 hours. Top panels show dot plots of B16ova cells depicting surface expression of VSV-G. Representative photographs showing cytopathic effects (CPE) (bottom panels) after 24 hours. HI: Heat-inactivated VSV; UVI: ultraviolet-inactivated VSV; FF: Formalin-fixed VSV. B. Using 96-well plates, 5×103 B16ova melanoma cells were infected with either live or inactivated VSVs at an MOI of 1.0. The number of viable cells was measured using MTT assay at the indicated time points postinfection. Values are averages of triplicate samples (± SEM) and representative of 2 independent experiments. C. Kaplan-Meier survival plot of subcutaneous B16ova tumor-bearing C57Bl/6 mice treated with six intratumoral injections of either live VSV or inactivated forms of VSV (5×108 pfu/injection). *p<0.05, **p<0.01, ***p<0.001.